Ivantis, an Irvine, CA-based company that designs, develops and commercializes new technologies to treat eye disease, has received $17m in the second round of financing.
Investors include New Enterprise Associates and Delphi Ventures.
The company intends to use the capital to expand clinical activities for the Hydrus, its intracanalicular (“in the canal”) scaffold for treatment of primary open angle glaucoma. In details, the funds will be used to support multiple randomized controlled trials around the world, including in the United States.
Ivantis’ Hydrus device, which recently received CE mark approval, is placed through a minimally invasive, microsurgical procedure and is designed to reduce eye pressure by reestablishing the patient’s natural outflow pathway.
Established in 2007, the company is led by President and CEO Dave Van Meter.